GlycoMimetics, Inc.

NasdaqCM:GLYC Stock Report

Market Cap: US$15.5m

GlycoMimetics Future Growth

Future criteria checks 0/6

GlycoMimetics's earnings are forecast to decline at 37.2% per annum while its annual revenue is expected to grow at 85.7% per year. EPS is expected to grow by 59.4% per annum.

Key information

-37.2%

Earnings growth rate

59.4%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate85.7%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Apr 2025

Recent future growth updates

Recent updates

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

Jun 27
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Mar 20
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Nov 19
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Jan 30
Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

Aug 03

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Mar 16

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Earnings and Revenue Growth Forecasts

NasdaqCM:GLYC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-94-77N/A1
12/31/2026N/A-47-32N/A1
12/31/2025N/A-26-12N/A1
12/31/2024N/A-38-31-31N/A
9/30/20240-40-35-35N/A
6/30/20240-39-36-36N/A
3/31/20240-37-34-34N/A
12/31/20230-37-35-35N/A
9/30/2023N/A-38-35-35N/A
6/30/2023N/A-37-35-35N/A
3/31/20230-42-44-44N/A
12/31/20220-47-47-46N/A
9/30/20220-54-51-51N/A
6/30/20220-63-60-60N/A
3/31/20220-64-57-57N/A
12/31/20211-63-58-57N/A
9/30/20211-62-54-54N/A
6/30/20212-58-49-49N/A
3/31/20212-58-50-50N/A
12/31/202010-51-39-39N/A
9/30/202010-50-42-42N/A
6/30/20209-50-44-44N/A
3/31/20209-51-41-41N/A
12/31/2019N/A-58-52-52N/A
9/30/2019N/A-57-49-49N/A
6/30/2019N/A-55-46-46N/A
3/31/2019N/A-51-48-47N/A
12/31/2018N/A-48-43-43N/A
9/30/2018N/A-44N/A-42N/A
6/30/2018N/A-40N/A-38N/A
3/31/2018N/A-37N/A-31N/A
12/31/2017N/A-33N/A-30N/A
9/30/2017N/A-32N/A-27N/A
6/30/20170-32N/A-29N/A
3/31/20170-32N/A-30N/A
12/31/20160-32N/A-30N/A
9/30/20160-32N/A-31N/A
6/30/20160-32N/A-10N/A
3/31/201620-13N/A-9N/A
12/31/201520-13N/A-8N/A
9/30/201520-11N/A-7N/A
6/30/201520-11N/A-26N/A
3/31/201515-13N/A-10N/A
12/31/201415-11N/A-4N/A
9/30/201415-8N/A-4N/A
6/30/201415-5N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GLYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GLYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GLYC is forecast to have no revenue next year.

High Growth Revenue: GLYC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GLYC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 13:36
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlycoMimetics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.